



Early Stage Breast Cancer Research Studies

Neoadjuvant trials

- **ptDNA/Liquid tumor biopsy**
To determine if it is possible to use blood samples to predict response to treatment in breast cancer patients receiving preoperative (or neoadjuvant) therapy.
<https://clinicaltrials.gov/ct2/show/NCT02743910>
- **ALTERNATE: neoadjuvant endocrine therapy, Stage II-III**
To determine whether neoadjuvant endocrine therapy with Fulvestrant or the combination of Anastrozole and Fulvestrant is more effective than Anastrozole alone when given before surgery.
<https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/view?cdrid=753769>
<https://clinicaltrials.gov/ct2/show/NCT01953588>
- **Lymph node study**
A trial to evaluate the role of axillary lymph node dissection and radiation therapy after chemotherapy.
<https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/view?cdrid=751211>
<https://clinicaltrials.gov/ct2/show/NCT01901094>

Adjuvant trials

- **PALLAS: Palbociclib & endocrine vs endocrine alone**
To compare 5 years endocrine therapy with 2-year Palbociclib treatment **versus** at least 5 years endocrine therapy alone in patients with histologically confirmed Hormone Receptor Positive/HER2 negative invasive early breast cancer.
<https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/view?cdrid=777467>
<https://clinicaltrials.gov/ct2/show/NCT02513394>
- **BWEL: Weight loss in locally advanced BC after completion of SOC**
A trial to determine if losing weight may help prevent breast cancer from coming back (recurring).
<https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/view?cdrid=781402>
<https://clinicaltrials.gov/ct2/show/NCT02750826>
- **ABC**
A trial to determine if ASA is beneficial after standard therapy.
<https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/view?cdrid=785097>
<https://clinicaltrials.gov/ct2/show/NCT02927249>
- **S1418: Pembrolizumab vs placebo in TNBC patients**
A Pembrolizumab immunotherapy trial for triple negative breast cancer patients with residual disease after chemotherapy.
<https://clinicaltrials.gov/ct2/show/NCT02954874>

- **RU011501:** adjuvant GM-CSF vaccination for triple negative
An immunotherapy trial for triple negative breast cancer patients using a vaccine following standard therapy.
<https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/view?cdrid=780418>
<https://clinicaltrials.gov/ct2/show/NCT02593227>
Anticipated to open at Inova Fall 2017
- **OLYMPIA: Olaparib in patients with BRCA+ mutations**
An Olaparib trial for HER2 negative patients with a BRCA mutation.
<https://clinicaltrials.gov/ct2/show/NCT02032823>

Inova Breast Cancer Research Contact information:

Research Team:

Mary J. Wilkinson, MD

David M. Heyer M.D.

Kathleen K. Harnden, MD

Margaret S. Howard, MD

Parisa Saifollahi, RN

Joshelynn Asis, RN

Natalia Girard, B.S. CCRC

Neva Kassis, B.S.

Inova Breast Cancer Research

Main Clinic

Inova Breast Cancer Email

General Clinical Trial Information

(703) 720-5210

(703) 207-0733

breastcancerresearch@inova.org

<https://clinicaltrials.gov/>

<https://www.breastcancertrials.org>